Blood
Articles in this Issue
STOP & GO: discontinuing TPO-RA in chronic ITP
GSI: myeloma—cold case closed?
Genetic iron overload aggravates, and pharmacological iron restriction improves, MDS pathophysiology in a preclinical study
Abstract Although iron overload is a common feature in myelodysplastic syndromes (MDS), it remains unclear how iron excess is detrimental for disease pathophysiology. Taking advantag...
Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy
Abstract Chimeric antigen receptor (CAR) T cells and bispecific antibodies targeting B-cell maturation antigen (BCMA) have significantly advanced the treatment of relapsed and refrac...
Lower-intensity therapy for good-risk B-ALL
Iron accelerates MDS progression
Long-term follow-up of the STOPAGO study
Abstract In an open prospective, multicenter study enrolling 48 selected patients with chronic immune thrombocytopenia who achieved complete response for 1 year on thrombopoietin rec...
Doubling down on GPRC5D in multiple myeloma
Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma
Abstract Despite several approved therapies, multiple myeloma (MM) remains an incurable disease with high unmet medical need. “Off-the-shelf” T-cell bispecific antibodies (TCBs) targ...
Outcomes in patients with <i>ETV6</i>::<i>RUNX1</i> or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies
Abstract Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients...
The current landscape of frontline large B-cell lymphoma trials
Abstract At least 25% to 35% of patients with large B-cell lymphoma (LBCL) are not cured with frontline treatment, with generally poor subsequent outcomes. This motivates ongoing and...
Building the future management of follicular lymphoma with T-cell–redirecting strategies
Abstract Follicular lymphoma (FL) usually requires multiple lines of therapy, and disease control remains largely insufficient with conventional chemoimmunotherapy. Several T-cell–re...
CD123 to the rescue
In APL, 2 targets are better than 1!
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Abstract Treatment outcomes for acute promyelocytic leukemia (APL) have improved with the widespread use of targeted therapy with all-trans retinoic acid (ATRA) and arsenic trioxide...